A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients

Inclusion Criteria:

* Male or female patients age 18-75 year-old;
* ECOG 0 - 2;
* Newly diagnosed or previously treated Ph+ CML patients in accelerated or blastic Phase;
* Adequate organ function;
* Written informed consent prior to any study procedures being performed.

Exclusion Criteria:

* Patients in Chronic and Blastic Phases;
* Previously treated with Flumatinib;
* Previously documented T315I mutations;
* Previous therapy within protocol defined timeframe, including:

  * hydroxyurea within 24 hr,
  * Imatinib or Nilotinib or Dasatinib within 28 days)
* Cardiac dysfunction ;
* History of congenital or acquired bleeding disorders unrelated to CML;
* Central nervous system leukemia;
* Previous malignancy except CML;
* Acute or chronic liver or severe kidney disease unrelated to CML;
* Pregnant, breastfeeding, child bearing potential but failed to take effective contraception.